Change in the management at Eckert & Ziegler BEBIG

Effective as of 1 January 2012 Abel Luzuriaga will be appointed as Managing Director of Eckert & Ziegler BEBIG  and to the Board of Directors of the company. Together with Dr. Edgar Löffler the previous Vice President Sales will be responsible for the daily business. He thus replaces Dr. Gunnar Mann who will dedicate himself to other tasks in the Eckert & Ziegler Group in future. A host of further restructurings are associated with the change in the management board of Eckert & Ziegler BEBIG of which the Board of Directors promises a greater power of impact for the company.

"With Mr Luzuriaga a distinguished practical expert will move into top management, who can refer to a career of more than 20years in sales and to successes as Managing Director in the industry", Dr. Andreas Eckert, Chairman of the Supervisory Board, explained. "We are pleased that we were able to win him for this task. With his international experience he will help us to develop new markets in particular in the emerging markets."

Before his start at Eckert & Ziegler BEBIG in January 2011 as Head of Sales for France, Italy, Spain, Great Britain and India Luzuriaga worked as Managing Director at Theranostic Medizintechnik GmbH, the German branch of the Dutch brachytherapy specialist Nucletron B.V. for more than ten years. From 2007 he moreover bore the responsibility as Head of Sales for the economic area of Europe, the Middle East and Africa at Nucletron.

He started his professional career at Asea Brown Boveri AG (Mannheim) as commissioning engineer; he subsequently held leading positions in international sales in several companies (Dainippon Screen GmbH, OTESA Siemens Ecuador).

"I am very excited to take over the responsibility as Managing Director of Eckert & Ziegler BEBIG as it continues to grow into one of the global leaders in offering complete solutions in the brachytherapy", said Abel Luzuriaga. "I look forward, with the support of its strong team and its innovative product development, to expanding and driving its engagement with the worldwide radiation oncology society."